A threat that resides on a doorknob has a subtle unnerving quality. It is waiting on a bedrail. It moves through hospital hallways with a patience that most pathogens lack, but it doesn’t make a big announcement. That kind of threat is Candida auris, which has been confirmed in 27 U.S. states as of late July 2026, with over 3,400 cases found so far this year alone.
It’s worth stopping to consider those figures. At the same time last year, there were about 4,290 cases. Thus, things appear marginally better in one specific sense. However, this fungus’s history has never truly turned around. It was first discovered in 1996, officially recognized as a new species in Japan in 2009, and only found in the United States in 2013. It has been increasing year after year, settling into medical facilities in a way that few pathogens do: persistently, obstinately, and with a resistance to antifungal drugs that truly worries experts in infectious diseases.
With 873 reported cases this year, California leads the nation. Tennessee has recorded 283, while Texas comes in second with 433. These communities aren’t just randomly contracting a seasonal illness. In hospitals, assisted living facilities, and intensive care units, where patients already have limited resources, the cases are concentrated.
Although drug resistance is a significant factor, it is not the only factor that makes managing Candida auris particularly challenging. Numerous strains are resistant to at least one class of antifungal drugs. Some people oppose multiple. For precisely this reason, the CDC has designated it as a major threat to global health. However, how it spreads and how covertly it does so is the other issue. Unknowingly leaving traces of the fungus on surfaces, equipment, and even caregivers’ hands as they move between patients, a person can have the fungus on their skin and exhibit no symptoms at all. The chain of transmission may be untraceable by the time a clinical infection develops in a susceptible patient.
Patients who are already engaged in other conflicts are the most vulnerable. individuals whose immune systems are compromised. those using catheters or ventilators. long-term residents of nursing homes. It’s a sobering image—healthy people strolling through urban streets aren’t being stalked by this pathogen. It locates those who are most vulnerable to it.
Fever, chills, low blood pressure, a drop in body temperature, and exhaustion are among the symptoms that infected patients may experience. It can become truly life-threatening when it enters the bloodstream in severe cases. Invasive infection is the clinical term, but in practice, it means that doctors are faced with a limited number of options and a patient who might not have much time.
Speaking with public health observers, it seems that Candida auris is a preview of the kind of treatment-resistant infections that stealthily build up inside healthcare systems over years, depleting resources and options, rather than something of apocalyptic proportions. Although still increasing, the rate of new cases has slowed since 2022, according to the CDC. That is a significant, if modest, development. It implies that some containment measures, such as thorough screening, strict surface disinfection, and isolation techniques, are working.
It’s really unclear if that slowing trend will continue. 6,304 clinical cases were reported nationwide in 2024, and 2026 is expected to significantly increase that number. The fact that the instruments hospitals require—such as improved rapid diagnostics, broader-spectrum antifungals, and a more coordinated national surveillance system—are in different stages of development but haven’t yet been fully implemented at scale is frustrating.
The majority of healthy individuals currently have few direct causes for concern. However, this isn’t an abstract public health statistic for anyone who has a family member in a long-term care facility or is going to be hospitalized with invasive medical equipment. It’s a genuine and current issue. It is not alarmist to ask about infection control procedures, comprehend the risks, or remain informed. In the context of healthcare, where not all threats are immediately apparent, it’s simply practical.
Candida auris moves silently. That’s exactly why it’s important to pay attention to.
